RSV Risk: Who Is Most Vulnerable to Severe Infection?

Respiratory syncytial virus (RSV) is a ubiquitous seasonal virus causing mild, cold-like illness in most healthy children and adults. However, it is the leading cause of lower respiratory tract infection (LRTI)—bronchiolitis and pneumonia—in infants and a major cause of severe respiratory disease in older adults and immunocompromised individuals.

Highest-Risk Groups for Severe RSV

  • Infants and young children: Especially under 6 months (peak hospitalization age 2–3 months). Immature airways, small caliber, limited immune memory.
  • Premature infants (born <37 weeks, especially <29 weeks): Underdeveloped lungs, reduced maternal antibody transfer.
  • Children with underlying conditions: Congenital heart disease (especially hemodynamically significant), chronic lung disease of prematurity (BPD), neuromuscular disorders, immunodeficiency, Down syndrome.
  • Older adults (≥65 years): Age-related immune senescence, comorbidities, reduced respiratory reserve. RSV causes ~60,000–160,000 hospitalizations and 6,000–10,000 deaths annually in U.S. adults ≥65.
  • Immunocompromised individuals: HIV/AIDS (low CD4), hematologic malignancy, transplant recipients (solid organ, HSCT), immunosuppressive therapy (chemo, biologics, high-dose steroids).
  • Adults with chronic cardiopulmonary disease: COPD, asthma, heart failure, coronary artery disease.
  • Residents of long-term care facilities: High attack rates, severe outcomes.

Why These Groups?

Common threads: impaired viral clearance (immature or senescent immunity), reduced respiratory reserve (small airways, comorbidities), and dysregulated immune response causing immunopathology. RSV infects ciliated epithelial cells → sloughing, mucus plugs, bronchiolar obstruction → air trapping, atelectasis, hypoxemia.

Prevention Tools by Group

  • Infants: Nirsevimab (Beyfortus®)—long-acting monoclonal antibody, single dose for all infants <8 months entering first RSV season; high-risk children 8–19 months entering second season. Palivizumab (Synagis®)—monthly IM for high-risk preemies (being replaced by nirsevimab).
  • Pregnant people: Maternal RSVpreF vaccine (Abrysvo®) 32–36 weeks gestation → transplacental antibodies protect infant 0–6 months.
  • Older adults (≥60): RSVpreF (Abrysvo®) or RSVPreF3 (Arexvy®) vaccines—single dose, high efficacy vs. LRTI.
  • All: Hand hygiene, masking, staying home when sick, limiting infant exposure to sick contacts.

RSV is not "just a cold" for vulnerable populations. New prevention tools (maternal vaccine, infant mAb, older adult vaccines) are transformative—discuss with your provider.

Viral Infections - Related Articles